01—Abstract
Summary
Summary of the 10-Q filed November 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health Inc. (CAH) reported its first quarter fiscal year 2025 results, demonstrating resilience and strategic execution despite the significant impact of the OptumRx contract expiration.
While consolidated revenue saw a 4% decrease to $52.3 billiona, primarily due to the OptumRx contract loss, the company achieved a 12% increase in non-GAAP operating earnings to $625 million, driven by strong performance in branded and specialty pharmaceuticals, including the favorable impact of early COVID-19 vaccine distribution. Operationally, the company navigated the loss of OptumRx revenue by focusing on growth from existing customers and cost-saving measures.
The acquisition of Integrated Oncology Network (ION) for $1.1 billionb was announced, signaling a strategic move to expand its oncology services. Despite a net cash used in operating activities of $1.6 billion, largely due to working capital unwinding from OptumRx and opioid settlement payments, Cardinal Health maintained a solid liquidity position and continued its capital deployment strategy through share repurchases and dividend payments.
02—Key points
Key Highlights
- Consolidated revenue decreased 4% to $52.3 billion, primarily impacted by the expiration of OptumRx contracts.
- Non-GAAP operating earnings increased 12% to $625 million, driven by growth in branded and specialty pharmaceuticals and COVID-19 vaccine distribution.
- Non-GAAP diluted EPS rose 9% to $1.88.
- The company announced a $1.1 billion acquisition of Integrated Oncology Network (ION) to expand its oncology offerings.
- Net cash used in operating activities was $1.6 billion, impacted by OptumRx contract unwinding and opioid settlement payments.
- The company has $3.2 billion remaining under its share repurchase authorization, and repurchased $375 million in the quarter.
- The company reported compliance with its net leverage ratio covenant of no more than 3.75-to-1.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Cardinal Health Inc kept $0.01.
- Revenue$52.28B100.0%
- Cost of revenue−$50.38B96.4%
- Gross profit$1.90B3.6%
- Operating costs−$1.33B2.6%
- Operating income$568.0M1.1%
- Interest, other & tax−$152.0M0.3%
- Net income$416.0M0.8%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed November 1, 2024Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $52.28B$54.65B | −4.3% |
| Cost of Revenue | $50.38B$52.91B | −4.8% |
| Gross Profit | $1.90B$1.74B | +9.1% |
| SG&A Expenses | $1.28B$1.19B | +7.7% |
| Operating Income | $568.00M-$32.00M | +1875.0% |
| Interest Expense | $32.00M$11.00M | +190.9% |
| Net Income | $416.00M-$12.00M | +3566.7% |
| EPS (Basic) | $1.71$-0.05 | +3520.0% |
| EPS (Diluted) | $1.70$-0.05 | +3500.0% |
| Shares Outstanding (Basic) | 243.00M249.00M | −2.4% |
| Shares Outstanding (Diluted) | 245.00M249.00M | −1.6% |
05—Questions
Frequently Asked Questions
What was the primary driver for the revenue decline in Q1 FY2025?
The primary driver for the 4% decrease in consolidated revenue to $52.3 billion was the expiration of the pharmaceutical distribution contracts with OptumRx at the end of June 2024. Sales to OptumRx represented 17% of consolidated revenue in fiscal year 2024.
How did Cardinal Health offset the revenue impact from the OptumRx contract expiration?
Cardinal Health is offsetting the impact through a combination of onboarding new customers, growth from existing customers, and implementing cost-saving measures. The company also benefited from increased contributions from branded and specialty pharmaceutical products and the early seasonal launch of COVID-19 vaccine distribution.
What is the financial impact of the Integrated Oncology Network (ION) acquisition?
Cardinal Health announced an agreement to acquire ION for $1.1 billion in cash. This acquisition is expected to expand its suite of clinical and practice management solutions for independent community oncology practices. The transaction is subject to customary closing conditions, including regulatory approvals.
What is the current cash position and liquidity outlook?
At September 30, 2024, Cardinal Health had $2.9 billion in cash and equivalents. The company reported net cash used in operating activities of $1.6 billion for the quarter, largely due to the unwinding of net working capital from the OptumRx contracts and opioid settlement payments. Cardinal Health believes it has adequate capital resources to fund its operations and future needs, with additional liquidity available through its commercial paper program and revolving credit facility.
06—Continue